Entresto Earns Expanded Indication for Chronic Heart Failure
The well-known and commonly prescribed heart failure drug, Entresto (sacubitril and valsartan) has helped many patients suffering with heart failure since its initial approval in 2015. Recently, the FDA announced approval for an expanded indication for reducing the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Read more.

FDA Approves Evkeeza for Homozygous Familial Hypercholesteremia
Homozygous familial hypercholesterolemia (HoFH) is a rare genetic condition characterized by extremely elevated low-density lipoprotein cholesterol (LDL-C). In the pivotal phase III ELIPSE HoFH trial, researchers discovered that adding evinacumab to standard lipid-lowering therapies, such as statins and proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors, diminished LDL-C by nearly 50% at 24 weeks compared with placebo. Read more.

Study Compares Metoprolol Versus Carvedilol After Acute MI
Prescribers often prescribe beta-blockers following a myocardial infarction (MI); however, no specific beta-blocker is recommended over another. Researchers conducted a study to compare metoprolol versus carvedilol in a post-MI cohort. According to the recent study, carvedilol and metoprolol largely benefit patients with acute MI and left ventricular (LV) dysfunction in the same manner, but a key difference is seen in patients with depressed LV ejection fraction. Read more.